# Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

> **NCT04068181** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 72 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Talimogene laherparepvec
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04068181
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-22
- **Primary completion:** 2021-08-19
- **Final completion:** 2024-02-26
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068181, "Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04068181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*